Detection of Bladder Tumors After 30 Min Instillation of Hexvix
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Open Prospective Within Patient, Phase IIa Study of Hexvix Flexible Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer After 30 Minutes Instillation of Hexvix in Patients With Known or Suspicion of Bladder Cancer|
- Number of lesions [ Time Frame: An average of 15 min (during cystoscopy) ] [ Designated as safety issue: No ]
- Drug related adverse events [ Time Frame: From time of drug instillation until 24 hours after cystoscopy ] [ Designated as safety issue: Yes ]
|Study Start Date:||December 2011|
|Study Completion Date:||June 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
This study is an open, prospective, within patient, controlled, multi-center, Phase IIa study in patients with bladder cancer.
The bladder of all patients will be instilled with 50 mL Hexvix® 8 mM solution and evacuated after 30 minutes. After bladder evacuation, the bladder will be examined under white light cystoscopy using the Karl Storz flexible videocystoscope. Tumors visible under white light will be mapped. Then the bladder is evaluated with blue light and lesions seen by blue light will be mapped. Biopsies of all visible tumors will be taken using both white and blue light prior to resection of all lesions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01551407
|Munich, Germany, D-81377|
|Principal Investigator:||Alexander Karl, MD||Department of Urology, LMU Munich, Germany|